Saratov JOURNAL of Medical and Scientific Research

Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy

Year: 2015, volume 11 Issue: №3 Pages: 428-431
Heading: Dermatovenerology Article type: Review
Authors: Reshetko O.V., Lutsevich К.А., Nelyubova 0.I.
Organization: Saratov State Medical University

The article presents pharmacoeconomics is an essential component of health technology assessment and the appraisal of medicines for use by patients. As a comparatively young discipline, its methods continue to evolve. Pharma-coeconomic analyses encompass cost — minimization, cost — utility, cost — benefit, and cost — effectiveness studies, providing essential information critical for optimization of pharmacotherapy, optimal health-care resource allocation and drug development success.

1. Ritter JM. Money makes the world go round: the pervasiveness of pharmacoeconomics. Br J Clin Pharmacol 2008; 66: 755-757
2. Drummond M. Pharmacoeconomics: friend or foe? Ann Rheum Dis 2006; 65 (Suppl III): Ш44-Ш47
3. Pang F. Design, analysis and presentation of multinational economic studies: The need for guidance. Pharmacoeconomics 2002; 20: 75-90
4. Petrov VI. Pharmacoepidemiology and pharmacoeconomics in Russia: the status of the problems and prospects of development. Klinicheskie issledovanija lekarstv v Rossii 2002; (1): 8-10
5. Edlin R, Round J, Hulme С, McCabe С. Cost effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol 2010; 70: 350-355
6. Mohan L, Kumari KM, Dikshit H, Biswas NR. Pharma-coeconomic exercise for undergraduate medical students. Int J Basic Clin Pharmacol 2014; 3: 1099-1100
7. Kulkarni U, Deshmukh YA, Moghe VV, Rege N, Kate M. Introducing pharmacoeconomics (PE) in medical undergraduate curriculum. Afr J Pharm Pharmacol 2010; 4: 27-30
8. Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28: 1069-1074
9. Singh J. International society for pharmacoeconomics and outcomes research. Indian J Pharmacol 2006; 38: 376-377
10. Lyles A. Recent trends in pharmacoeconomics: Needs and unmet needs. Eur J Pharm Sci 2008; 34: S7-S24
11. Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008; 26: 769-779
12. Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; 12:409-418
13. Bodrogi J, Kalo Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol 2010; 159: 1367-1373
14. Honig PK, Lalonde R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin Pharmacol Ther 2010; 87: 247-251
15. Honig PK. Comparative effectiveness: The fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther 2011; 89: 151-156
16. Krammer H. Pharmacoeconomic analyses — chance or 4th hurdle for innovative drugs. Wien Med Wochenschr 2006; 156:606-611
17. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002; 20 (Suppl. 3): 11-29
18. Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: costs-moving beyond the acquisition price for drugs. J Clin Pharm Ther 2003; 28: 73-79
19. Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: costminimization analysis — when are two therapies equal? J Clin Pharm Ther 2003; 28: 145-150
20. Lopert R, Lang DL, Hill S. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis — a technique for decision-making at the margin. J Clin Pharm Ther 2003; 28: 243-249
21. Brinsmead R, Hill S. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? J Clin Pharm Ther 200328: 339-346
22. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17: 501-513
23. Khanna D, Tsevat J. Health-related Quality of Life — an introduction. Am J Managed Care 2007; 13: S218-S223
24. Vemer P, Molken MPMH. Largely ignored: the impact of the threshold value for a QALY on the importance of a transfer-ability factor. Eur J Health Econ 2011; 12: 397-404
25. Nelyubova Ol, Utz SR, Sazanova GYu, Morrison AV Cost-effectiveness of therapy in patients with psoriasis. Saratov Journal of Medical Scientific Research 2014; (3): 508-511
27. Hughes D, Reynolds DJ. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. Clin Med 2009; 9: 490-492
28. Rohilla A, Kumar A, Keshari R, et al. Pharmacoeconomics: An overview. International Journal of Research in Pharmacy and Chemistry 2013; 3: 64-68
29. Waldman SA, TerzicA. Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther 2008; 84:179-182
30. Iram M, Rani S, Hiremath R. Pharmacoeconomics: Need for the day. Indian J Pharm Pract 2009; 2: 16-18
31. Vegter S, Boersma C, Rozenbaum M, et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26: 569-587
32. Rani S., Hiremath R. Methods of Pharmacoeconomic Evaluation —An Overview. Journal of Pharmaceutical Research 2015; 27-28
33. Reginster JY, Ethgen O. Personalized Medicine: Pharmacoeconomic aspects. Revue medicale de Liege 2014; 70 (5-6): 339-342
34. Murthy RK, DeLong LK, Chen SC. Critical Appraisal of Pharmacoeconomic Studies. Evidence-Based Dermatology 2014;3:62-65.

2015_03-01_428-431.pdf249.78 KB

No votes yet